VANCOUVER, BC, May 28, 2021 /CNW/ – MYND Life Sciences Inc. (CSE: MYND) (“MYND“), a drug research and development company focused on novel psychedelic drug development, diagnostic approaches and pharmaceuticals, is pleased to announce the formation of its scientific advisory board (“SAB”). The SAB is comprised of international industry experts and pioneers in the fields of neuropsychopharmacology, genetics, immunology, psychedelics, medical research, and clinical trials.
“We are incredibly excited about the roster of advisors we have been able to attract to MYND’s scientific advisory board,” stated Dr. Lyle Oberg, MYND’s Chief Executive Officer. “We have continued to believe that the science and patents being advanced and refined by MYND’s Dr. Wilfred Jefferies and his team could attract the most pre-eminent and distinguished minds in science from across the globe, and the advisory board we have assembled thus far serves to validate our enthusiasm,” continued Dr. Oberg.
Members of the scientific advisory board include:
Dr. Michael Brownstein has over 40 years of research experience in the fields of genetics, endocrinology, and pharmacology. He earned his bachelor’s degree from Columbia University; completed his graduate training at the University of Chicago, where he earned an M.D. and Ph.D. in pharmacology; and received his clinical training at the Boston Children’s Hospital. He then moved to the National Institutes of Health to work with Julius Axelrod, recipient of a Nobel Prize in 1970 for his studies in the field of neuropharmacology and remained at NIH after completing his fellowship. Dr. Brownstein served at the NIH as Chief of the Laboratory of Genetics of the National Institute of Mental Health and the National Human Genome Research Institute; and for two years as the Scientific Director of the NIMH Intramural Research Program
Mark A. Geyer, Ph.D., is Distinguished Professor of Psychiatry and Neurosciences Emeritus at the University of California San Diego (UCSD) and directs the Neuropsychopharmacology Unit of the Veterans Administration Mental Illness Research, Clinical, and Education Center. At UCSD, he is a founding member of the Consortium for Translational Research in Neuropsychopharmacology (CTRIN) and Translational Research in Psychophysiology, Exploration, and Cognition (TRIPEC) groups. In 1993, he co-founded the Heffter Research Institute, which pioneered and supported much of the scientific research that has prompted the exploration of psychedelics as potential therapeutics in humans. He has recently co-founded the Psychedelics and Health Research Initiative at UCSD, which is exploring the efficacy of psychedelics in the treatment of pain disorders.
Joseph Boyd Martin, M.D., Ph.D., Edward R. and Anne G. Lefler Professor of Neurobiology Emeritus, served as Dean of the Harvard Faculty of Medicine from 1997 to 2007. Born in Bassano, Alberta, Canada in 1938, Dr. Martin received his premedical and medical education at the University of Alberta, Edmonton, earning the M.D. degree in 1962. He completed a residency in neurology in 1966 and a fellowship in neuropathology in 1967 at Case Western Reserve University in Cleveland, Ohio, and received his Ph.D. in anatomy from the University of Rochester in 1971. Dr. Martin began his career in academic medicine at McGill University in Montreal, where he eventually became Chair of the Department of Neurology and Neurosurgery in 1977. In 1978, he joined the faculty of Harvard Medical School in Boston as the Bullard Professor of Neurology and Chief of the Neurology service at the Massachusetts General Hospital. In 1984, he was appointed the Julieanne Dorn Professor of Neurology at Harvard. Dr. Martin’s research focused on hypothalamic regulation of pituitary hormone secretions and on the application of neurochemical and molecular genetics to better understand the causes of neurological and neurodegenerative disease.
Dr. John Trowsdale is an Emeritus Professor of Immunology at the University of Cambridge UK. After postdoctoral work in Paris, at Scripps in California, and in Oxford, he moved to Cancer Research UK in London. In the early 1980s, Trowsdale was one of the first to clone HLA genes and to study their impact on susceptibility to infection, autoimmunity and cancer. Trowsdale has made other contributions to the field of immunogenetics, in particular identifying components of antigen processing such as TAP transporters, the immunoproteasome and the tapasin-related TAPBPR. More recently the group developed novel, high-throughput methods for typing polymorphic receptors on Natural Killer Cells and uncovered their roles in regulating inflammation. In 2002 he received the ASHI Rose Payne distinguished scientist award. He received the Ceppellini Award at the Annual Conference of EFI in Sofia 2004 and delivered the Festenstein Lecture at the BSHI meeting in Liverpool in 2012. He was elected a Fellow of the Academy of Medical Sciences in 2000 and a Fellow of Trinity Hall Cambridge in 2009. John’s interest in MYND is in further development of modulation of cell behaviour through cell surface receptors.
“We have established a very accomplished and diverse group of international experts that will undoubtedly help advance MYND’s research and ultimately provide novel solutions to Major Depressive Disorder and other neurological diseases,” stated Dr. Wilfred Jefferies, MYND’s Chief Science Officer. “As a scientist and a researcher, it is of great advantage to have such a World-Class group of Scientists to contribute to our research and development,” continued Dr. Jefferies.
ABOUT MYND LIFE SCIENCES
MYND Life Science Inc. is a leading life sciences company focused on improving mental health. The Company has confirmed access to Health Canada psilocybin research and development through licenses to Chief Science Officer, Dr. Wilfred Jefferies. Patents have been filed based on therapeutic approaches to treat diseases of the Central Nervous System using neuroactive agents including psychedelics and other compounds. Research and development is currently underway.
CONTACT INFORMATION
Dr. Lyle Oberg, CEO
Email: IR@myndsciences.com
Phone: 954-401-8686
Web: www.myndsciences.com
Forward-Looking Information
This news release contains forward-looking statements and information within the meaning of applicable securities legislation. Often, but not always, forward-looking statements and information can be identified by the use of words such as “plans”, “expects” or “does not expect”, “is expected”, “estimates”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. Forward-looking statements or information involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of MYND to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements or information contained in this news release.
Risks, uncertainties, and other factors involved with forward-looking information could cause actual events, results, performance, prospects, and opportunities to differ materially from those expressed or implied by such forward-looking information.
SOURCE Mynd Life Sciences Inc.
